Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$51.57
-0.4%
$22.44
$7.57
$53.85
$2.01B0.68580,200 shs942,952 shs
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$5.41
-0.6%
$4.69
$3.74
$8.61
$2.10B1.132.00 million shs1.68 million shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$20.91
+1.9%
$17.93
$14.14
$28.40
$1.20BN/A710,307 shs355,457 shs
Progyny, Inc. stock logo
PGNY
Progyny
$23.78
+1.6%
$22.41
$13.39
$26.76
$2.04B1.321.42 million shs880,075 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
0.00%+12.88%+281.09%+384.47%+212.93%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
0.00%+24.49%+28.91%-6.85%-3.72%
Omada Health, Inc. stock logo
OMDA
Omada Health
0.00%+7.94%+16.78%+2,052,999,900.00%+2,052,999,900.00%
Progyny, Inc. stock logo
PGNY
Progyny
0.00%+2.41%+6.36%+8.84%+11.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celcuity, Inc. stock logo
CELC
Celcuity
1.1113 of 5 stars
1.52.00.00.02.83.30.0
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
3.2338 of 5 stars
3.44.00.00.02.72.50.6
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
1.4952 of 5 stars
1.42.00.00.03.32.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
3.00
Buy$50.60-1.88% Downside
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
2.86
Moderate Buy$8.5057.12% Upside
Omada Health, Inc. stock logo
OMDA
Omada Health
3.00
Buy$24.5717.51% Upside
Progyny, Inc. stock logo
PGNY
Progyny
2.73
Moderate Buy$24.904.71% Upside

Current Analyst Ratings Breakdown

Latest OMDA, PGNY, CELC, and LFST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $66.00
8/15/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $70.00
8/8/2025
Progyny, Inc. stock logo
PGNY
Progyny
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$28.00
8/8/2025
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.50 ➝ $9.00
8/8/2025
Omada Health, Inc. stock logo
OMDA
Omada Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $28.00
8/8/2025
Omada Health, Inc. stock logo
OMDA
Omada Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$21.00 ➝ $24.00
8/8/2025
Omada Health, Inc. stock logo
OMDA
Omada Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $24.00
8/8/2025
Progyny, Inc. stock logo
PGNY
Progyny
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$26.00 ➝ $28.00
7/28/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$28.00 ➝ $60.00
7/28/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $50.00
7/28/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$3.11 per shareN/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$1.25B1.68$0.04 per share137.19$3.78 per share1.43
Omada Health, Inc. stock logo
OMDA
Omada Health
$209.83M5.74N/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
$1.17B1.75$0.35 per share67.81$4.96 per share4.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$111.78M-$3.45N/AN/AN/AN/A-126.74%-60.59%N/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$57.44M-$0.05N/AN/AN/A-1.23%-1.11%-0.76%11/6/2025 (Estimated)
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/A0.00N/AN/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
$54.34M$0.5940.3136.582.294.28%10.69%7.12%N/A

Latest OMDA, PGNY, CELC, and LFST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.90-$1.04-$0.14-$1.04N/AN/A
8/7/2025Q2 2025
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$0.03-$0.01+$0.02-$0.01$345.05 million$345.31 million
8/7/2025Q2 2025
Omada Health, Inc. stock logo
OMDA
Omada Health
-$0.15-$0.22-$0.07-$0.24$55.17 million$61.37 million
8/7/2025Q2 2025
Progyny, Inc. stock logo
PGNY
Progyny
$0.42$0.19-$0.23$0.19$315.70 million$332.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
N/AN/AN/AN/AN/A
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
1.14
6.61
6.61
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
0.19
1.48
1.48
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
N/A
2.70
2.70

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
85.50%
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
Progyny, Inc. stock logo
PGNY
Progyny
94.93%

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
15.78%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
6.60%
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
Progyny, Inc. stock logo
PGNY
Progyny
9.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4038.91 million32.77 millionOptionable
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
10,218388.94 million363.27 millionOptionable
Omada Health, Inc. stock logo
OMDA
Omada Health
84957.58 millionN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
31085.98 million77.90 millionOptionable

Recent News About These Companies

Truist Financial Remains a Hold on Progyny (PGNY)
Progyny (NASDAQ:PGNY) Shares Gap Up Following Analyst Upgrade
Progyny, Inc. Announces Second Quarter 2025 Results
Progyny (NASDAQ:PGNY) Price Target Raised to $28.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$51.57 -0.22 (-0.42%)
Closing price 04:00 PM Eastern
Extended Trading
$51.61 +0.04 (+0.09%)
As of 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

LifeStance Health Group stock logo

LifeStance Health Group NASDAQ:LFST

$5.41 -0.03 (-0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$5.40 -0.01 (-0.18%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Omada Health stock logo

Omada Health NASDAQ:OMDA

$20.91 +0.38 (+1.85%)
As of 04:00 PM Eastern

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.

Progyny stock logo

Progyny NASDAQ:PGNY

$23.78 +0.38 (+1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$24.06 +0.27 (+1.16%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.